Navigation Links
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Date:2/24/2013

12 years of age and older who have moderate to severe persistent allergic asthma caused by year-round allergens in the air and are uncontrolled on inhaled corticosteroids. Xolair helps reduce the number of asthma attacks in people with allergic asthma who still have asthma symptoms even though they are taking inhaled steroids. Xolair should not be used to treat other allergic conditions. Xolair is not a rescue medicine and should not be used to treat sudden asthma attacks. Xolair should not be used in children under 12 years of age.

Omalizumab is being jointly developed by Novartis and Genentech. In the US, Xolair® (omalizumab) for subcutaneous use in appropriate allergic asthma patients is co-promoted by Novartis Pharmaceuticals Corporation and Genentech.

About Xolair® (omalizumab) for subcutaneous use
Important Safety Information: Appropriate Moderate-Severe Allergic Asthma Patients

Xolair should always be injected in a doctor's office. Patients should read the Medication Guide before starting Xolair treatment and before each and every treatment.

A severe allergic reaction called anaphylaxis has happened in some patients after they received Xolair. Anaphylaxis is a life-threatening condition and can lead to death. Patients must seek emergency medical treatment right away if symptoms occur.

Signs and symptoms of anaphylaxis include:

  • wheezing, shortness of breath, cough, chest tightness, or trouble breathing
  • low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of "impending doom"
  • flushing, itching, hives, or feeling warm
  • swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing

Anaphylaxis from Xolair can happen:

  • right after receiving a Xolair injection or hours later
  • after
    '/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
6. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
7. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
8. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
9. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
10. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  In a sweeping analysis assessing the ... T1D Exchange researchers conclude that there remains considerable ... across all age groups, but especially for adolescents and ... of diabetes treatment, underscoring the need to address barriers ... can help type 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
(Date:5/21/2015)... , May 21, 2015  Cardica, Inc. (Nasdaq: CRDC ... Greg Watson , the company,s vice president of operations, ... company,s common stock, at a per share exercise price of ... stock option was granted pursuant to Cardica, Inc.,s Inducement Plan, ... May 2015 under Rule 5653(c)(4) of the Nasdaq Global Market ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Cardica Announces New Employment Inducement Grant 2
... Milestone Scientific Inc. (OTCQB: MLSS), the recognized leader in ... its 2010 year-end results for the 12 months ended ... Commission on Wednesday, March 30, 2011. Milestone,s ... 4, 2011 beginning at 4:15 PM Eastern Daylight Savings ...
... YORK, April 1, 2011 NeoStem, Inc. (NYSE Amex: ... company with operations in the U.S. and China, is today ... activities: Revenues for the year ended December ... 2009.  2010 was the first full year that results for ...
Cached Medicine Technology:Milestone Scientific Will Host Its 2011 Conference Call on Monday, April 4, 2011 2NeoStem Provides Results for 2010 and an Update on Recent Activities 2NeoStem Provides Results for 2010 and an Update on Recent Activities 3NeoStem Provides Results for 2010 and an Update on Recent Activities 4NeoStem Provides Results for 2010 and an Update on Recent Activities 5
(Date:5/24/2015)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) May 24, ... sees many patients for concerns about hair loss. ... loss, it is clear that there are environmental factors ... of hormone that can contribute. Since they offer a ... aspects of the peri and post-menopausal woman, they can ...
(Date:5/24/2015)... EnviroLeather™ by LDI, a leader in ... classic, rugged leather grain with enhanced stain resistance ... ink, to be easily removed. The collection is ... healthcare, hospitality and education environments. , InkGard Plus ... developing products that are more sustainable, less toxic ...
(Date:5/24/2015)... 2015 Medicx Media Solutions ... executive Jay Krihak as its head of programmatic ... up its expertise and leadership position in the ... Health sectors. , Krihak is an experienced, award-winning ... Krihak led sales planning teams for mobile platform ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... May 23, 2015 On May 16, the ... The event was a 5k mud obstacle run that raised ... 2 million people worldwide, and the reason we participated was ... Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of ... Society.” , The event was not only attended by eXtreme ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2
... part of health, and assessment of sleep habits should be ... in the September 18 issue of Archives of Internal Medicine ... devoted to studies of sleep and health. ,"The ... as an indicator of health and quality of life and ...
... the times, warns the U.S. Food and Drug Administration// (FDA). ... Georgia that was believed to occur due to the consumption ... three cases were reported on September 15. Other consumers of ... not have any complaints as they had properly refrigerated it., ...
... official government assessment of a ?1 million public consultation project ... fake//. ,Your Health, Your Care, Your Say was ... a say in a White Paper on health published this ... complained that they had no influence on the final policies.14% ...
... A recent report by the Ministry in Jamaica has revealed ... a paper that has now come before the House of// ... virus live healthy lives for several years without developing the ... the performance of the National HIV/STI Control Programme, and states ...
... lot more funds are needed from the rich countries to ... five by two-thirds.// ,Five times more money is ... one of the series of papers published online by the ... the journal, UNICEF and the Norwegian government. , ...
... to improve HIV/AIDS treatment and evolve better prevention strategies, ... into an agreement this month, to formally seal their ... free nation. It is well known that, The Clinton ... to eliminate AIDS from the planet. ...
Cached Medicine News:Health News:Incorporate Sleep Evaluation into Routine Medical Care 2Health News:A million Pound Public consultation - declared a sham!! 2Health News:Child death reduction needs five times more funds 2
... For fast, single-solution staining, Hema-Quik ... Dip slides into stain solution ... transfer to deionized water for ... a second time by dipping ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
This Wright-Giemsa is a dual-use stain for peripheral blood and bone marrow smears. It produces somewhat darker results when compared with Giemsa, particularly in the blue to magenta shades....
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
Medicine Products: